CORE ADANIPORTS+0.24% BIRET-0.24% BRIGADE-0.85% DLF-1.17% EMBASSY+1.10% GMRAIRPORT+0.00% GODREJPROP+0.19% IRB+3.46% LODHA-0.98% LT-1.76% MAHLIFE-1.64% MINDSPACE-1.39% NCC-0.64% OBEROIRLTY-0.14% PHOENIXLTD+0.11% PRESTIGE-0.22% SOBHA+0.95% as of 2026-08-26 14:06 UTC

The Annexure

Desk Healthcare Gennex Laboratories Ltd

Gennex Laboratories Ltd

BSE 531739 GENNEX INE509C01026
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Filing rhythm · 60 trading days

11 filings · 2 material · busiest 2026-06-10

What it files

Filings

11 in the window

  1. 17 August 2026

    Newspaper Publication

    Newspaper Publication

    Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....

    Company Update / Newspaper Publication View filing →

  2. 14 August 2026

    Board Outcome

    Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30, 2026

    In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....

    Board Meeting / Outcome of Board Meeting View filing →

  3. 14 August 2026

    Results

    Un-Audited Financial Results For The Quarter Ended June 30, 2026

    In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited Standalone and Consolidated Financial Statement for the Quarter ended ....

    Result / Financial Results View filing →

  4. 30 July 2026

    Newspaper Publication

    Newspaper Publication

    Pursuant to Regulation 47 of SEBI (LODR), Regulations, 2015, please find enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company scheduled to ....

    Company Update / Newspaper Publication View filing →

  5. 29 July 2026

    Board Meeting

    Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

    Gennex Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. The Unaudited Financial ....

    Board Meeting / Board Meeting View filing →

  6. 17 July 2026

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from the M/s R&D Infotech Private ....

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  7. 23 June 2026

    Trading Window

    Closure of Trading Window

    Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window ....

    Insider Trading / SAST / Closure of Trading Window View filing →

  8. 10 June 2026

    SAST

    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd

    Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →

  9. 10 June 2026

    SAST

    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd

    Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →

  10. 10 June 2026

    SAST

    Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

    The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....

    Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →

  11. 10 June 2026

    SAST

    Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

    The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....

    Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →